Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00387764 · OUTCOME

Number of Participants With the Indicated Shift From Baseline in Blood Pressure at Any Time Post-Baseline

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer · Source last updated 2014-01-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From Baseline to investigational product discontinuation (up to 6.230 years)

What was measured

Blood pressure measurements included systolic blood pressure (SBP, millimeters of mercury \[mmHg\]) and diastolic BP (DBP). The number of participants with a post-Baseline shift from Baseline in blood pressure (\<90 mmHg, 90 to 139 mmHg, 140 to 169 mmHg, \>=170 mmHg) was assessed.

Analysis population: ATS Population

Groups in this outcome

Pazopanib 800 mg

Participants received pazopanib 800 milligrams (mg) once daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg80

Reported measurements

SBP, <90 mmHg
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg1Not reportedNot reportedNot reportedNot reported
SBP, 90 to 139 mmHg
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg29Not reportedNot reportedNot reportedNot reported
SBP, 140 to 169 mmHg
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg44Not reportedNot reportedNot reportedNot reported
SBP, >=170 mmHg
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg6Not reportedNot reportedNot reportedNot reported
DBP, <90 mmHg
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg1Not reportedNot reportedNot reportedNot reported
DBP, 90 to 139 mmHg
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg32Not reportedNot reportedNot reportedNot reported
DBP, 140 to 169 mmHg
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg46Not reportedNot reportedNot reportedNot reported
DBP, >=170 mmHg
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    SBP, <90 mmHg
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        29
    title
    SBP, 90 to 139 mmHg
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        44
    title
    SBP, 140 to 169 mmHg
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    SBP, >=170 mmHg
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    DBP, <90 mmHg
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        32
    title
    DBP, 90 to 139 mmHg
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        46
    title
    DBP, 140 to 169 mmHg
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    DBP, >=170 mmHg
denoms
  1. counts
    1. group Id
      OG000
      value
      80
    units
    Participants
description
Blood pressure measurements included systolic blood pressure (SBP, millimeters of mercury \[mmHg\]) and diastolic BP (DBP). The number of participants with a post-Baseline shift from Baseline in blood pressure (\<90 mmHg, 90 to 139 mmHg, 140 to 169 mmHg, \>=170 mmHg) was assessed.
groups
  1. description
    Participants received pazopanib 800 milligrams (mg) once daily.
    id
    OG000
    title
    Pazopanib 800 mg
param Type
NUMBER
population Description
ATS Population
reporting Status
POSTED
time Frame
From Baseline to investigational product discontinuation (up to 6.230 years)
title
Number of Participants With the Indicated Shift From Baseline in Blood Pressure at Any Time Post-Baseline
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice